Centers | ||
|
|
|
Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | BLAVATNIK CENTER for Drug Discovery | FDA Oncology Center of Excellence Project Catalyst |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
The BLAVATNIK CENTER for Drug Discovery (BCDD) is a fully integrated center for translational research, based at Tel Aviv University, that comprises medicinal chemistry, biological target identification and computer-assisted drug design units under... Read more |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
Partnerships |
Events |
Jobs |
Vanderbilt and Astra Zeneca to Develop New Drugs to Treat Psychosis and Other Brain DisordersUnder a new research collaboration agreement, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Astra Zeneca will work together to develop compounds that act on M4 muscarinic acetylcholine receptor. The agreement entails research... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Eisiai Partners with Johns Hopkins Brain Science InstituteEisiai Partners with Johns Hopkins Brain Science Institute ("BSi") an institute which is part of Johns Hopkins University to develop new drugs for neurological diseases. Under this joint collaboration, BSi will provide validated targets to Eisai... View all |
No EVENTS for listing |
No Job Posts |
